Linked Life Data

1777246

Source:http://linkedlifedata.com/resource/pubmed/id/1777246

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1992-3-9
pubmed:abstractText
The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p less than 0.001). For patients with more advanced disease (stages II, III, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0284-186X
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
941-5
pubmed:dateRevised
2009-5-12
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Cellular B-2 microglobulin expression as a prognostic indicator in renal cell carcinoma.
pubmed:affiliation
Department of Urology, Ben Gurion University of the Negev, Beer-Sheva, Israel.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't